AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32974413 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanophthalmic eyes
Number of subjects: 32
Study 32974614 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent online training
Number of subjects: 0
Study 32974614 — intervention group
Group type: EXPERIMENTAL
Intervention: In-depth structured training via a quality improvement project
Number of subjects: 0
Study 32974614 — intervention group
Group type: EXPERIMENTAL
Intervention: SEEK model
Number of subjects: 0
Study 32974614 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-driven implementation strategies
Number of subjects: 0
Study 32974614 — intervention group
Group type: EXPERIMENTAL
Intervention: Training strategies
Number of subjects: 0
Study 32974687 — intervention group
Group type: EXPERIMENTAL
Intervention: MR 4D flow imaging
Number of subjects: 44
Study 32974773 — intervention group
Group type: EXPERIMENTAL
Intervention: LP-irinotecan TACE
Number of subjects: 50
Study 32975045 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor (PPI) treatment
Number of subjects: 374
Study 32975059 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombocytopenia
Number of subjects: 1202
Study 32975059 — intervention group
Group type: COMPARATOR
Intervention: No thrombocytopenia
Number of subjects: 1202
Study 32975528 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP integration into family planning services at Title X clinics
Number of subjects: 0
Study 32975528 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP uptake, persistence, and adherence among female patients
Number of subjects: 0
Study 32975632 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturation diving at 401 kPa for 36 hours (intervention group)
Number of subjects: 26
Study 32975632 — intervention group
Group type: COMPARATOR
Intervention: Control group (no saturation diving)
Number of subjects: 26
Study 32975711 — intervention group
Group type: EXPERIMENTAL
Intervention: Early combination therapy with two glucose-lowering drugs
Number of subjects: 0
Study 32975711 — intervention group
Group type: COMPARATOR
Intervention: Stepwise approach starting with metformin
Number of subjects: 0
Study 32975869 — intervention group
Group type: EXPERIMENTAL
Intervention: Isatuximab 20 mg/kg QW/Q2W
Number of subjects: 33
Study 32976514 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-annual MDA (ivermectin 0.2 mg/kg + albendazole 400 mg)
Number of subjects: 0
Study 32976514 — intervention group
Group type: COMPARATOR
Intervention: Annual MDA (ivermectin 0.2 mg/kg + albendazole 400 mg)
Number of subjects: 0
Study 32976514 — intervention group
Group type: COMPARATOR
Intervention: Annual MDA
Number of subjects: 0
Study 32976514 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-annual MDA
Number of subjects: 0
Study 32976514 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MDA regimens
Number of subjects: 0
Study 32977309 — intervention group
Group type: EXPERIMENTAL
Intervention: 124I-8H9 monoclonal antibody (124I-omburtamab) administered by CED
Number of subjects: 7
Study 32977309 — intervention group
Group type: EXPERIMENTAL
Intervention: Second infusion of 124I-8H9 monoclonal antibody (124I-omburtamab)
Number of subjects: 7
Study 32977309 — intervention group
Group type: EXPERIMENTAL
Intervention: First and second infusions of 124I-8H9 monoclonal antibody (124I-omburtamab)
Number of subjects: 7
Study 32977351 — intervention group
Group type: EXPERIMENTAL
Intervention: Niprisan
Number of subjects: 212
Study 32977351 — intervention group
Group type: COMPARATOR
Intervention: Placebo or conventional treatment (including blood transfusion and hydroxyurea)
Number of subjects: 212
Study 32977785 — intervention group
Group type: EXPERIMENTAL
Intervention: Free musical training programme
Number of subjects: 171
Study 32977798 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch intervention
Number of subjects: 3
Study 32977802 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term glycemic variability (GV)
Number of subjects: 396
Study 32977906 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 1600
Study 32977906 — intervention group
Group type: COMPARATOR
Intervention: Standing position
Number of subjects: 1600
Study 32977906 — intervention group
Group type: EXPERIMENTAL
Intervention: Right side of the body (standing)
Number of subjects: 1600
Study 32977906 — intervention group
Group type: EXPERIMENTAL
Intervention: Right side of the body (supine)
Number of subjects: 1600
Study 32978101 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine and serine/threonine kinase inhibitors (TKIs)
Number of subjects: 0
Study 32978101 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of at least three concomitant medications
Number of subjects: 0
Study 32978191 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 0
Study 32978191 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 32978195 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical prediction model derived using logistic regression
Number of subjects: 370
Study 32978195 — intervention group
Group type: EXPERIMENTAL
Intervention: External validation using the Therapeutic Hypothermia After Paediatric Cardiac Arrest trial dataset
Number of subjects: 370
Study 32978206 — intervention group
Group type: EXPERIMENTAL
Intervention: Wireless sensor (myAngel VitalSigns, Devinnova, Montpellier, France)
Number of subjects: 115
Study 32978206 — intervention group
Group type: COMPARATOR
Intervention: Standard bedside monitor (Carescape Monitor B850, GE Healthcare, Chicago, Illinois)
Number of subjects: 115
Study 32978212 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccine (at birth)
Number of subjects: 6012
Study 32978212 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG reactors (having a 2-month reaction)
Number of subjects: 6012
Study 32978212 — intervention group
Group type: EXPERIMENTAL
Intervention: Reaction size tertiles
Number of subjects: 6012
Study 32978212 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccine (4-week evaluation)
Number of subjects: 6012
Study 32978218 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led educational programme consisting of individual semi-structured interviews and follow-up telephone interviews over 1 year.
Number of subjects: 182
Study 32978218 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 182
Study 32978233 — intervention group
Group type: EXPERIMENTAL
Intervention: High Glycemic Burden
Number of subjects: 0
Study 32978233 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 32978352 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine solution
Number of subjects: 114
Study 32978352 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution
Number of subjects: 114
Study 32979106 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (D) 75 mg/m²
Number of subjects: 0
Study 32979106 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin
Number of subjects: 0
Study 32979106 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of docetaxel and pegylated liposomal doxorubicin
Number of subjects: 0
Study 32979511 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 143
Study 32979535 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intraperitoneal pressure (IPP) at 6 mm Hg and warmed, humidified carbon dioxide gas
Number of subjects: 30
Study 32979560 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive brexpiprazole 2-3 mg/day for 8 weeks
Number of subjects: 9
Study 32979640 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients walking over 350 m
Number of subjects: 516
Study 32979640 — intervention group
Group type: COMPARATOR
Intervention: Other groups (walking less than 350 m)
Number of subjects: 516
Study 32979785 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with clinically relevant anxiety (A+)
Number of subjects: 118
Study 32979785 — intervention group
Group type: COMPARATOR
Intervention: Patients without clinically relevant anxiety (A-)
Number of subjects: 118
Study 32979984 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant treatment with intravenous paclitaxel (200 mg/m2) and nivolumab
Number of subjects: 46
Study 32979984 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant treatment with intravenous paclitaxel and nivolumab
Number of subjects: 46
Study 32980206 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep spindle activity in patients with COS
Number of subjects: 17
Study 32980206 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-rapid eye movement (NREM) sleep EEG power and coherence in the sigma band (11-16 Hz)
Number of subjects: 17
Study 32980206 — intervention group
Group type: EXPERIMENTAL
Intervention: Deficit in power and coherence of spindles
Number of subjects: 17
Study 32980364 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 270
Study 32980364 — intervention group
Group type: COMPARATOR
Intervention: Control (recent ACE inhibitor/ARB initiation/dose change)
Number of subjects: 270
Study 32980370 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 nights of pulse oximetry (PO) at home
Number of subjects: 103
Study 32980370 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple study nights using ambulatory oxygen saturation monitoring
Number of subjects: 103
Study 32980834 — intervention group
Group type: EXPERIMENTAL
Intervention: ω-3 fatty acids and low-dose aspirin as adjuncts to periodontal debridement
Number of subjects: 1
Study 32981423 — intervention group
Group type: EXPERIMENTAL
Intervention: Women without diabetes mellitus
Number of subjects: 14793
Study 32981423 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with diabetes mellitus
Number of subjects: 14793
Study 32981423 — intervention group
Group type: COMPARATOR
Intervention: Men without diabetes mellitus
Number of subjects: 14793
Study 32981423 — intervention group
Group type: COMPARATOR
Intervention: Men with diabetes mellitus
Number of subjects: 14793
Study 32982148 — intervention group
Group type: EXPERIMENTAL
Intervention: GoCheck Kids (GCK) photoscreener
Number of subjects: 131
Study 32982148 — intervention group
Group type: EXPERIMENTAL
Intervention: 2WIN photoscreener
Number of subjects: 131
Study 32982148 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinomax autorefractor
Number of subjects: 131
Study 32982210 — intervention group
Group type: EXPERIMENTAL
Intervention: Enjoying Breathing Program intervention including online and face-to-face courses for health care providers, standard therapy, self-management education, rehabilitation exercises, and follow-up every 3 months.
Number of subjects: 0
Study 32982210 — intervention group
Group type: EXPERIMENTAL
Intervention: Enjoying Breathing Program intervention
Number of subjects: 0
Study 32982387 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative dinalbuphine sebacate (DS)
Number of subjects: 44
Study 32982387 — intervention group
Group type: COMPARATOR
Intervention: Post-operative morphine
Number of subjects: 44
Study 32982388 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported physical function
Number of subjects: 79
Study 32982388 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance-based physical function
Number of subjects: 79
Study 32982388 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective physical function
Number of subjects: 79
Study 32982388 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain and non-adaptive coping
Number of subjects: 79
Study 32982388 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive coping
Number of subjects: 79
Study 32982388 — intervention group
Group type: EXPERIMENTAL
Intervention: Social-emotional dysfunction
Number of subjects: 79
Study 32982393 — intervention group
Group type: EXPERIMENTAL
Intervention: a-tDCS/HS
Number of subjects: 48
Study 32982393 — intervention group
Group type: EXPERIMENTAL
Intervention: a-tDCS
Number of subjects: 48
Study 32982393 — intervention group
Group type: EXPERIMENTAL
Intervention: HS
Number of subjects: 48
Study 32982393 — intervention group
Group type: EXPERIMENTAL
Intervention: s-tDCS/HS
Number of subjects: 48
Study 32982924 — intervention group
Group type: EXPERIMENTAL
Intervention: Canal repositioning maneuver
Number of subjects: 24
Study 32982933 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified Anthocyanins, dosage and duration not available
Number of subjects: 0
Study 32982933 — intervention group
Group type: COMPARATOR
Intervention: Control group, details not available
Number of subjects: 0
Study 32982944 — intervention group
Group type: EXPERIMENTAL
Intervention: High Dose of Atorvastatin
Number of subjects: 0
Study 32982944 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 32982950 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy of Virtual Reality and Transcranial Direct Current Stimulation
Number of subjects: 0
Study 32982950 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 32982963 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 293
Study 32983160 — intervention group
Group type: EXPERIMENTAL
Intervention: Thirty-eight-negative kinase 1 (TNK1) intervention
Number of subjects: 0
Study 32983160 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 32983243 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week weight loss camp including aerobic exercise and dietary control
Number of subjects: 79
Study 32983551 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Number of subjects: 114
Study 32983551 — intervention group
Group type: COMPARATOR
Intervention: LowGI/nutrigenetic diet
Number of subjects: 114
Study 32983557 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative tattooing of suspicious axillary lymph node with India ink at the time of core needle biopsy during SLNB.
Number of subjects: 40
Study 32983839 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus patient-tailored adherence interventions
Number of subjects: 438
Study 32983839 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 438
Study 32983965 — intervention group
Group type: EXPERIMENTAL
Intervention: GZ17-6.02 (602) + Doxorubicin
Number of subjects: 0
Study 32983965 — intervention group
Group type: EXPERIMENTAL
Intervention: GZ17-6.02 (602) alone
Number of subjects: 0
Study 32983965 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin + GZ17-6.02
Number of subjects: 0
Study 32983991 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1-based chemoradiotherapy followed by consolidation chemotherapy with S-1
Number of subjects: 0
Study 32984371 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive drug monitoring of β-Lactam antibiotics using sweat analysis
Number of subjects: 0
Study 32985119 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized nonshivering cold exposure
Number of subjects: 44
Study 32985406 — intervention group
Group type: EXPERIMENTAL
Intervention: Pittsburgh Sleep Quality Index (PSQI)
Number of subjects: 203
Study 32985406 — intervention group
Group type: EXPERIMENTAL
Intervention: PSQI components (poorer sleep quality and greater sleep disturbance)
Number of subjects: 203
Study 32985406 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased sleep latency and daytime sleepiness
Number of subjects: 203
Study 32985724 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical AF ablation
Number of subjects: 2391
Study 32985924 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemigland cryoablation
Number of subjects: 61
Study 32987448 — intervention group
Group type: COMPARATOR
Intervention: Probiotics
Number of subjects: 3034
Study 32987448 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics
Number of subjects: 3034
Study 32987448 — intervention group
Group type: COMPARATOR
Intervention: Fusidic acid ointment
Number of subjects: 3034
Study 32987448 — intervention group
Group type: COMPARATOR
Intervention: Mupirocin ointment
Number of subjects: 3034
Study 32987448 — intervention group
Group type: COMPARATOR
Intervention: Specialist breastfeeding education
Number of subjects: 3034
Study 32987448 — intervention group
Group type: COMPARATOR
Intervention: Anti-secretory factor-inducing cereal
Number of subjects: 3034
Study 32987448 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint massage
Number of subjects: 3034
Study 32987448 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast massage and low frequency pulse treatment
Number of subjects: 3034
Study 32987824 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance tests (OGTT) with doses of 25 g, 75 g, and 125 g
Number of subjects: 16
Study 32987824 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoglycaemic intravenous (i.v.) glucose infusions (IIGI)
Number of subjects: 16
Study 32988240 — intervention group
Group type: EXPERIMENTAL
Intervention: ECEQ-T (Turkish version of the European Child Environment Questionnaire)
Number of subjects: 306
Study 32988240 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-retest reliability of ECEQ-T
Number of subjects: 306
Study 32988817 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-spectrum-beta-lactamase (ESBL)-producing members
Number of subjects: 0
Study 32988829 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acyclovir (10 mg/kg of body weight/6 h)
Number of subjects: 79
Study 32988829 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir
Number of subjects: 79
Study 32988829 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intravenous and oral acyclovir
Number of subjects: 79
Study 32988829 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 79
Study 32988939 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour change interventions delivered by Norwegian Healthy Life Centres (HLCs)
Number of subjects: 713
Study 32988948 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral steroids, intratympanic steroid injections, or a combination of both (exact dosages and durations not specified)
Number of subjects: 0
Study 32988948 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable prognostic model using prespecified candidate predictors
Number of subjects: 0
Study 32988996 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab and trastuzumab-emtansine (T-DM1)
Number of subjects: 31
Study 32989031 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment
Number of subjects: 65
Study 32989226 — intervention group
Group type: EXPERIMENTAL
Intervention: ODM-207 (2 mg/kg)
Number of subjects: 35
Study 32989425 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 7000
Study 32989495 — intervention group
Group type: EXPERIMENTAL
Intervention: Three cycles of abbreviated R-CHOP
Number of subjects: 0
Study 32989552 — intervention group
Group type: EXPERIMENTAL
Intervention: JTX-4014 (500 mg every 3 weeks or 1000 mg every 6 weeks)
Number of subjects: 18
Study 32989552 — intervention group
Group type: EXPERIMENTAL
Intervention: JTX-4014
Number of subjects: 18
Study 32989575 — intervention group
Group type: EXPERIMENTAL
Intervention: Severely food insecure women
Number of subjects: 371
Study 32989575 — intervention group
Group type: COMPARATOR
Intervention: Food-secure women
Number of subjects: 371
Study 32989612 — intervention group
Group type: EXPERIMENTAL
Intervention: TIMI 0-1 group (n=219)
Number of subjects: 329
Study 32989612 — intervention group
Group type: COMPARATOR
Intervention: TIMI 2-3 group (n=110)
Number of subjects: 329
Study 32989616 — intervention group
Group type: EXPERIMENTAL
Intervention: Episodic Future Thinking (EFT)
Number of subjects: 0
Study 32989616 — intervention group
Group type: COMPARATOR
Intervention: Control episodic recent thinking
Number of subjects: 0
Study 32989616 — intervention group
Group type: COMPARATOR
Intervention: Economic scarcity narrative
Number of subjects: 0
Study 32989776 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line tyrosine kinase inhibitors (TKIs)
Number of subjects: 431
Study 32989776 — intervention group
Group type: COMPARATOR
Intervention: Non-switchers
Number of subjects: 431
Study 32989776 — intervention group
Group type: EXPERIMENTAL
Intervention: Switchers
Number of subjects: 431
Study 32989856 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma treatment
Number of subjects: 4
Study 32990181 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16
Number of subjects: 8351
Study 32990181 — intervention group
Group type: EXPERIMENTAL
Intervention: Carcinogenic HPVs in nonavalent vaccine (HPV16,18,31,33,45,52,58)
Number of subjects: 8351
Study 32990181 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV types not vaccinated against (HPV35,39,51,56,59,66,68)
Number of subjects: 8351
Study 32990181 — intervention group
Group type: EXPERIMENTAL
Intervention: Other 27 non-carcinogenic genotypes
Number of subjects: 8351
Study 32990248 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral intervention
Number of subjects: 266
Study 32990248 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention
Number of subjects: 266
Study 32990248 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 266
Study 32990250 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-enabled clinical decision support system for physical activity and diet
Number of subjects: 0
Study 32990250 — intervention group
Group type: COMPARATOR
Intervention: Control group (no web-enabled clinical decision support system)
Number of subjects: 0
Study 32990324 — intervention group
Group type: COMPARATOR
Intervention: Mepolizumab (300 mg; three separate injections every four weeks for 52 weeks)
Number of subjects: 440
Study 32990324 — intervention group
Group type: COMPARATOR
Intervention: Mepolizumab (300 mg)
Number of subjects: 440
Study 32990324 — intervention group
Group type: COMPARATOR
Intervention: Etanercept (25 mg twice a week) or Belimumab (10 mg/kg on days 0, 14, 28 and every 28 days thereafter until 12 months after the last participant was randomised) with standard therapy
Number of subjects: 440
Study 32990324 — intervention group
Group type: COMPARATOR
Intervention: Etanercept (25 mg twice a week)
Number of subjects: 440
Study 32990629 — intervention group
Group type: EXPERIMENTAL
Intervention: Video directly observed therapy (VDOT) with smartphone app, weekly internet subscription, translated text message reminders, and incentives for adherence
Number of subjects: 144
Study 32990629 — intervention group
Group type: COMPARATOR
Intervention: Usual-care directly observed therapy (DOT)
Number of subjects: 144
Study 32990629 — intervention group
Group type: EXPERIMENTAL
Intervention: VDOT
Number of subjects: 144